The Business Research Company’s TNF Alpha Inhibitors Global Market Report 2021: COVID-19 Growth And Change To 2030
LONDON, GREATER LONDON, UK, April 6, 2021 /EINPresswire.com/ — Our reports have been revised for market size, forecasts, and strategies to take on 2021 after the COVID-19 impact: https://www.thebusinessresearchcompany.com/global-market-reports
The growing prevalence of inflammatory diseases such as inflammatory bowel disease and psoriasis is a key factor driving the growth of the TNF alpha inhibitors market. Tumor necrosis factor-alpha (TNF alpha) inhibitors are commonly used in gastroenterology, dermatology and rheumatology for the treatment of various immune-mediated inflammatory diseases. Globally, the prevalence of inflammatory bowel disease (IBD) is about 0.5-24.5 cases for ulcerative colitis per 100,000 person-years and 0.1-16 cases for Crohn’s disease per 100,000 person-years, and overall, IBD prevalence is 396 cases per 100,000 people each year. Thus, the increasing number of cases of inflammatory diseases increases the demand for TNF alpha inhibitors contributing to the growth of the market.
The tumor necrosis factor inhibitor drugs market covered in this report is segmented by drug into remicade (infliximab), enbrel (etanercept), humira (adalimumab), cimzia (certolizumab pegol), simponi (golimumab). The TNF alpha inhibitors market is also segmented by route of administration into oral, subcutaneous, intravenous, others and by disease type into inflammatory bowel disease, psoriatic arthritis, ulcerative colitis (UC), rheumatoid arthritis, ankylosing spondylitis, others.
Read More On The Global TNF Alpha Inhibitors Market Report:
The global TNF alpha inhibitors market is expected to grow from $38.85 billion in 2020 to $40.33 billion in 2021 at a compound annual growth rate (CAGR) of 3.8%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The tumor necrosis factor (TNF) alpha inhibitors market is expected to reach $45.74 billion in 2025 at a CAGR of 3%.
Major players in the TNF alpha inhibitors market overview are AbbVie Inc., Amgen Inc., Johnson & Johnson Services, Inc., UCB S.A, Novartis International AG, Pfizer, Inc., Merck & co., Inc., Janssen Biotech, Ablynx, and Momenta Pharmaceuticals.
TNF Alpha Inhibitors Global Market Report 2021: COVID-19 Growth And Change To 2030 is one of a series of new reports from The Business Research Company that provides TNF alpha inhibitors market overview, forecast TNF alpha inhibitors market size and growth for the whole market, TNF alpha inhibitors market segments, and geographies, TNF alpha inhibitors market trends, TNF alpha inhibitors market drivers, restraints, leading competitors’ revenues, profiles, and market shares.
Request For A Sample Of The Global TNF Alpha Inhibitors Market Report:
Here Is A List Of Similar Reports By The Business Research Company:
Interleukin Inhibitors Global Market Report 2021: COVID-19 Growth And Change To 2030
Biosimilar Interleukins Global Market Report 2021: COVID-19 Growth And Change To 2030
Psoriatic Arthritis Treatment Global Market Report 2021: COVID-19 Growth And Change To 2030
Psoriasis Global Market Report 2021: COVID-19 Impact and Recovery to 2030
Microbiome Global Market Report 2021: COVID-19 Growth And Change to 2030
Interested to know more about The Business Research Company?
Read more about us at https://www.thebusinessresearchcompany.com/about-the-business-research-company.aspx
The Business Research Company is a market research and intelligence firm that excels in company, market, and consumer research. It has over 200 research professionals at its offices in India, the UK and the US, as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology. TBRC excels in company, market, and consumer research.
Call us now for personal assistance with your purchase:
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293